Research, made readable
Does extra vitamin D prevent fractures?
What the VITAL fracture trial can tell generally healthy adults, and why deficiency treatment is a different question.
Published: · Sources checked:
The short answer
VITAL did not establish a fracture-prevention benefit from added vitamin D in generally healthy midlife and older adults. It does not settle treatment of diagnosed deficiency.
Prepared with AI assistance from the linked sources. Not independently reviewed by a clinician. Source access and study limitations are stated in each article.
What the research says
VITAL: fractures over 5.3 years
- Who and what
- 25,871 US adults (men 50+, women 55+) were randomized to vitamin D₃ or placebo, and independently to omega-3 or its placebo. The reported vitamin D comparison accounts for that omega-3 assignment; it is not a test of one fixed combination. The vitamin D dose was 2,000 IU/day, not a personal recommendation. Median follow-up was 5.3 years.
- What changed
- Confirmed fractures affected 769/12,927 vitamin D participants versus 782/12,944 on placebo. Hazard ratio: 0.98 (95% confidence interval 0.89–1.08). The interval includes no effect; this is not an established 2% reduction.
- What this cannot tell us
- Participants were not selected for deficiency or osteoporosis. Results do not establish how to treat those conditions or apply directly to institutionalized older adults. Calcium was not assigned as a combined intervention.
- Sources and disclosure
- Full-text author manuscript reviewed. NIH-supported research. No substantial group difference in kidney stones or high blood calcium was reported; this does not establish safety for every dose or combination.
How many participants had a low starting blood level?
Baseline 25-hydroxyvitamin D results were available for 16,757 of the 25,871 participants. In that measured group, the mean was 30.7 ng/mL and 401 people (2.4%) were below 12 ng/mL. The 2.4% uses the measured group as its denominator, not the whole trial. These numbers describe the study population; they are not a personal diagnosis or blood-level target.
Does the low-level subgroup settle deficiency treatment?
No. In the exploratory subgroup below 12 ng/mL, first confirmed fractures occurred in 7 vitamin D participants and 8 placebo participants. The hazard ratio was 1.03, with a wide 95% confidence interval of 0.36–2.95. That interval is compatible with substantially lower or higher fracture hazard, so it is not a precise estimate or proof that treatment is ineffective. This subgroup was not prespecified, and the subgroup confidence intervals were not adjusted for multiple comparisons. The trial was not designed as a deficiency-treatment study.
Connect the evidence to your own questions
Do not change prescribed treatment based on this article. An interaction check cannot diagnose deficiency or choose your treatment.
Related ingredient guides
This opens the checker without selecting ingredients or adding doses. It checks the rules in our dataset; it cannot predict whether a supplement will work for you or prove a combination is safe.
Article history
· Clarified the separate omega-3 randomization, the measured baseline population and the uncertainty of the exploratory low-vitamin-D subgroup. Rechecked the original paper; the main fracture result and treatment caution are unchanged.
· First published. Focused source reading; no clinical review.
We update an article when a relevant trial, correction or safety finding changes the interpretation. The history records substantive changes; a routine check alone does not refresh the date.